RIXUBIS Approved for Treatment of Children with Hemophilia B

September 16, 2014

Baxter International Inc. announced on Monday, September 15 that the United States Food and Drug Administration (FDA) has approved RIXUBIS [Coagulation Factor IX (Recombinant)] for routine prophylactic treatment, control and prevention of bleeding episodes, and perioperative management in children with hemophilia B. RIXUBIS was the first recombinant factor IX (rFIX) approved for routine prophylaxis and […]

Sign up for E-mails, Dateline Newsletter, and other ways to stay connected.